Repare Therapeutics Inc (RPTX)

So what's the point of investing here if they are gonnna delist and only gonna get $1.82 a share 

News $2.56

Repare said it expects each Repare shareholder to get a cash payment of $1.82 per common share at closing, and in addition, each Repare shareholder will also get one non-transferable contingent value right for each share that entitles the holder to receive some cash payments.After completion of the deal, Repare will become a privately held company, and its shares will be delisted from Nasdaq, it said, adding the deal is expected to close in Q1 2026.

$2.09 + 26%

RPTX.................................................https://stockcharts.com/sc3/ui/?s=RPTX&p=W&b=5&g=0&id=p86431144783

RPTX...........................................a/h

Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

Jult 15, 2025

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A. (“Debiopharm”), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor.

“The exclusive worldwide licensing agreement with Debiopharm allows for the continued development of lunresertib, a novel PKMYT1 inhibitor, that has demonstrated encouraging results across multiple clinical trials in difficult-to-treat solid tumors. This agreement builds upon the success of Repare and Debiopharm’s existing collaboration studying the combination of lunresertib and Debio 0123,” said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. “Our recent business development efforts have continued to enable Repare to focus on the advancement of our clinical priorities and sustained value creation. We remain focused on two ongoing Phase 1 clinical trials with readouts expected in the second half of 2025: the LIONS trial evaluating our RP-1664 PLK4 inhibitor and the POLAR trial evaluating our RP-3467 Pol? ATPase inhibitor.”

Under the terms of the agreement, Repare will receive a $10 million upfront payment, and is eligible to receive up to $257 million in potential clinical, regulatory, commercial and sales milestones, including up to $5 million in potential near-term payments, and single-digit royalties on global net sales. Repare and Debiopharm entered into a clinical study and collaboration agreement in January 2024 to explore the synergy between lunresertib and Debio 0123, a potential best-in-class, brain penetrant and highly selective WEE1 inhibitor. Debiopharm will assume sponsorship of the MYTHIC study and take over existing and future development activities related to lunresertib.

“We are excited to enter into this worldwide license agreement with Repare for lunresertib. Based on very promising Phase 1/1b clinical data, we believe the combination of lunresertib and Debio 0123 is highly synergistic and could potentially drive rapid and deep tumor regressions,” said Bertrand Ducrey, CEO of Debiopharm. “We believe the synthetic lethality approach of lunresertib in combination with Debio 0123 will allow us to bring this innovative precision therapy to patients with difficult to treat cancers.”

Continued Prioritization of RP-3467 and RP-1664

Moving forward, Repare will remain focused on the advancement of its two ongoing Phase 1 clinical trials, POLAR and LIONS. The POLAR clinical trial is a multicenter, open-label, dose-escalation Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467, a small molecule inhibitor of polymerase theta (Pol?) that is a synthetic lethality target associated with BRCA mutations and other genomic alterations, alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma. Topline safety, tolerability and early efficacy data from the Phase 1 POLAR clinical trial of RP-3467 alone and in combination with olaparib is expected in the third quarter of 2025. The LIONS clinical trial is a first-in-human, multicenter, open-label Phase 1 clinical trial designed to investigate safety, pharmacokinetics, pharmacodynamics and the preliminary efficacy of RP-1664, a first-in-class, highly selective, oral inhibitor of Polo-like kinase 4 (PLK4) that is a synthetic lethality target associated with TRIM37 overexpression. Initial topline safety, tolerability and early efficacy data from the Phase 1 LIONS clinical trial of RP-1664 is expected in the fourth quarter of 2025.

About Repare Therapeutics Inc.

Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s clinical-stage pipeline includes RP-3467, a Phase 1 Pol? ATPase inhibitor and RP-1664, a Phase 1 PLK4 inhibitor. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.

Debiopharm’s Commitment to Patients

Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally.

For more information, please visit www.debiopharm.com

https://ih.advfn.com/stock-market/NASDAQ/repare-therapeutics-RPTX/stock-news/96434476/repare-therapeutics-enters-exclusive-worldwide-lic

$RPTX

RPTX, under $2

RPTX under $2

RPTX, under $2

$RPTX: Don't see any news yet........... but

Looks like you're close to breaking even......... bounced off the $0.90 lows and
now up to $1.30

Lemme know whats in the pipes.


Its been culled down to the shoulder blades.


GO $RPTX

I'm still buying. Big news coming one of these weeks !

RPTX....................https://stockcharts.com/h-sc/ui?s=RPTX&p=W&b=5&g=0&id=p86431144783

Rather odd to say the least. I feel bad for recommending this as a buy. Fast track status means FDA must answer within 60 days. MMs are showing no mercy and much greed ! upside to this will be extreme as well--in my opinion. Good luck !

No bottom to this or what?

RPTX............................https://stockcharts.com/h-sc/ui?s=RPTX&p=W&b=5&g=0&id=p86431144783

RPTX under $3

RPTX under $5

From that awful Cathie Wood
Repare Therapeutics (RPTX)
icon-rise-1
17%
Shares of Repare Therapeutics traded up ~17% on Thursday after the company announced10 its second-quarter financial results. During its Research and Development Day in the fourth quarter, management will present updates on the company’s preclinical pipeline and disclose the target for RP-1664. Repare Therapeutics is a precision oncology company searching for novel therapeutics targets by using its discovery platform, SNIPRX.

I believe we going to break 15 on today is close.

I believe we going hit 15 this week if not more....

Not alone bought on the news sold Friday 1290 flipped twice and long now again till 20 May flip along the way 15 next the deal is good stuff and the stock is down roche just put a seal of approval

RPTX: We just busted-through to a "LUCKY THIRTEEN DOLLARS" price!!! NOT quite to the MOON, as they say. But what-the-FLICK, I'll take it!!

RPTX: Something is UP!!!! INDEED, a shinny-new GREEN COLOR for our --- well, at least MY shares --- of RPTX!! RPTX just might have some UPDATE NEWS coming next Monday, Peeps!! (HA-HA-HA!!!)

RPTX: GREEN!!!! Green is beautiful!!! "GREEN-STOCKS-MATTER"!!!!!




"And by the way, iHub, I don't give a FLUCK if Morgan Fairchild just turned Sweet-116-Years old!!!!"

RPTX: Oooooops!!! You MM's can NOT keep our little GREEN-PRICE-Parrot away forever!!! So cut-that-out, you reprobate MM's!!!!

RPTX: I just LOVE being ALONE over here!! (However, click handy LINK, below, for the "Bee Gees" EPIC ballad with THAT name!!! Maybe the BEST "ballad" ever done!!! Yet I'll wager that NOBODY here as ever even HEARD about this song!!! HA-HA-HA!!!)

RPTX: Well, good morning, FOLKS!!! (Just trying to get a word in here edgewise is difficult, as you can see! We 'gots' so many POSTS here everyday, the iHub Algorithms simply can't handle the action!! )

In any event, GO-GO-GO-RPTX!!! Take us to the MOON today!! Well, at least maybe to the 'International SPACE STATION??? (HA-HA-HA!!!)

RPTX: NOT a bad day here.

RPTX: Hey, 'RA-40' Dude, your post is the BEST point of the DAY about this RPTX-Roche-Company partnership!! Indeed, THAT many SHARES traded at the circa $9-$12 price range is impressive. This Company has nice, BIG, upside PRICE potential. Big-Time-ROCHE didn't cement that HUGE deal today because RPTX is some Stinky-Pinky-Wanna-Be-Big-PHARMA, with scores of USELESS "Patents-Pending"; nor weekly (Elementary School) Petri-Dish-&-Test-Tube-Studies; nor Miraculous-Sick-MICE-Cures!

See-ya tomorrow!!!

No one noticing? Volume was 139 times normal

RPTX: May have a late-day RUN here, Folks!! Whether anyone likes it, or not!!! (HA-HA-HA!!!)


"Heck, ya never know WHAT-THE-FLUCK is gonna happen on these Stock Market GAMBLING CASINOS these days!!!!"

RPTX: They WILL notice this little GEM, Dude --- soon enough!!!

https://www.fool.com/investing/2022/06/02/why-repare-therapeutics-stock-is-skyrocketing-toda/

It huge news but no one noticing

RPTX: Now UP by a glorious 44%, Peeps & Homeboys!!! Don't miss the FUN -- let alone the PROFITS -- via this MONSTER Medical Science play!!! I guess nobody is YET paying any attention to today's NEWS about this little GEM!!! (HA-HA-HA!!!)

https://www.tipranks.com/news/article/2-insiders-hot-stocks-with-growth-potential/

https://finance.yahoo.com/news/repare-therapeutics-announces-worldwide-license-200500192.html

https://seekingalpha.com/news/3844736-rptx-stock-gains-as-roche-signs-licensing-deal-for-tumor-candidate

RPTX: Ain't gonna be CRICKETS in here for very much longer, Folks!!!!

https://www.tipranks.com/news/article/2-insiders-hot-stocks-with-growth-potential/

https://finance.yahoo.com/news/repare-therapeutics-announces-worldwide-license-200500192.html

https://seekingalpha.com/news/3844736-rptx-stock-gains-as-roche-signs-licensing-deal-for-tumor-candidate

RPTX: Yet another handy LINK (Fidelity) about this rather NICE news today for RPTX. (HA-HA-HA!!!)
https://eresearch.fidelity.com/eresearch/evaluate/news/basicNewsStory.jhtml?symbols=RPTX&pageno=&storyid=202206011618RTRSNEWSCOMBINED_FWN2XO0QP_1&provider=RTRSNEWS&product=COMBINED&

RPTX: Welcome aboard, Bro!!! This one is the proverbial, "Biggest No-Brainer In The History Of Mankind" routine!!! (Hey, I DO indeed realize that I am iHub's unoffical 'CLASS CLOWN'; but nevertheless, even FOOLS like me can pick-em ONCE in awhile!! HA-HA-HA!!!)


"Heck, I used to think that the ONLY time in my life that I ever got 'LUCKY', was winning a lousy Two-Dollar-Scratcher for TEN BUCKS in a 7/11-Store back in 1982! But with RPTX, I just hit the MOTHERLODE!!!! Bottom line, finally gettin' some RESPECT!!!!"

I am in

RPTX: Ya-all MISSED the take-off!! I am already well on my way to the MOON! Never been there, so it may be interesting!

"This is one small STEP for Mankind; but one GIANT LEAP for the bank account balance of iHub's own JUST-KEEP-TRYING Dude!!!" (HA-HA-HA!!!)

RPTX: Anybody gonna join me for a quick trip to the MOON today??? I can fly there all by MYSELF, but it sure gets LONELY way out there; but, I think I can MUSCLE-through-it, nevertheless. (HA-HA-HA!!)

https://www.marketwatch.com/story/roche-repares-licensing-deal-includes-milestone-payments-worth-up-to-12-billion-2022-06-02

https://pulse2.com/repare-therapeutics-rptx-stock-price-why-it-increased-over-20-today/

https://www.postregister.com/businessreport/healthcare/repare-therapeutics-announces-a-worldwide-license-and-collaboration-agreement-with-roche-for-camonsertib-rp-3500/article_a6d38b6f-626d-51f5-a151-9e0e435be816.html

https://www.marketbeat.com/instant-alerts/nasdaq-rptx-a-buy-or-sell-right-now-2022-06/


"Heck, last time I saw a stock like THIS rocketship, it landed on Planet JUPITER by lunchtime on Wall Street!"